Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Fourth-generation fluoroquinolones offer improved coverage
Fort Lauderdale, FL-The investigational fourth-generation fluoroquinolones moxifloxacin and gatifloxacin show prom-ising potential for providing broad- spectrum coverage against important gram-negative and gram-positive ocular pathogens, according to results of in vitro susceptibility testing presented at the annual meeting of the Association for Research in Vision and Ophthalmology.
Related Videos
Related Content
